CF PharmTech Signs Three-Year Strategic Partnership with JD Health for Exclusive Online Launch of Respiratory Portfolio

Bulletin Express03-23

CF PharmTech, Inc. (CF PharmTech) announced that it entered into a strategic cooperation agreement with JD Health International Inc. on 20 March 2026, appointing JD Health as the exclusive online launch platform for a series of new products in respiratory and rhinology therapeutics over the next three years.

Under the agreement, JD Health will: 1) Deploy its e-commerce and supply-chain infrastructure to support online sales and patient-service operations for CF PharmTech’s upcoming products; 2) Leverage its prescription‐management and patient-administration capabilities to accelerate commercialization efficiency; 3) Collaborate with CF PharmTech on internet-based chronic-disease management models.

CF PharmTech’s pipeline spans allergic rhinitis, chronic rhinosinusitis, asthma and chronic obstructive pulmonary disease, supplemented by programs targeting pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders. The company combines small-molecule and small-nucleic-acid drugs with inhalation delivery technologies—such as liposomal and siRNA platforms—to enhance efficacy-safety profiles through localized administration.

The board of CF PharmTech states that the partnership is expected to improve patient accessibility and bolster commercialization efficiency amid China’s large, long-term respiratory patient base. The agreement does not constitute a notifiable transaction under Hong Kong listing rules.

Shareholders and potential investors are advised to exercise caution when dealing in CF PharmTech’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185911468?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 08:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185911468","market":"hk","top_or_hot":-1,"title":"CF PharmTech Signs Three-Year Strategic Partnership with JD Health for Exclusive Online Launch of Respiratory Portfolio","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. (CF PharmTech) announced that it entered into a strategic cooperation agreement with JD Health International Inc. on 20 March 2026, appointing JD Health as the exclusive online launch platform for a series of new products in respiratory and rhinology therapeutics over the next three years.</p>\n<p>Under the agreement, JD Health will:  \n1) Deploy its e-commerce and supply-chain infrastructure to support online sales and patient-service operations for CF PharmTech’s upcoming products;  \n2) Leverage its prescription‐management and patient-administration capabilities to accelerate commercialization efficiency;  \n3) Collaborate with CF PharmTech on internet-based chronic-disease management models.</p>\n<p>CF PharmTech’s pipeline spans allergic rhinitis, chronic rhinosinusitis, asthma and chronic obstructive pulmonary disease, supplemented by programs targeting pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders. The company combines small-molecule and small-nucleic-acid drugs with inhalation delivery technologies—such as liposomal and siRNA platforms—to enhance efficacy-safety profiles through localized administration.</p>\n<p>The board of CF PharmTech states that the partnership is expected to improve patient accessibility and bolster commercialization efficiency amid China’s large, long-term respiratory patient base. The agreement does not constitute a notifiable transaction under Hong Kong listing rules.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in CF PharmTech’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech Signs Three-Year Strategic Partnership with JD Health for Exclusive Online Launch of Respiratory Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech Signs Three-Year Strategic Partnership with JD Health for Exclusive Online Launch of Respiratory Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-23 08:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. (CF PharmTech) announced that it entered into a strategic cooperation agreement with JD Health International Inc. on 20 March 2026, appointing JD Health as the exclusive online launch platform for a series of new products in respiratory and rhinology therapeutics over the next three years.</p>\n<p>Under the agreement, JD Health will:  \n1) Deploy its e-commerce and supply-chain infrastructure to support online sales and patient-service operations for CF PharmTech’s upcoming products;  \n2) Leverage its prescription‐management and patient-administration capabilities to accelerate commercialization efficiency;  \n3) Collaborate with CF PharmTech on internet-based chronic-disease management models.</p>\n<p>CF PharmTech’s pipeline spans allergic rhinitis, chronic rhinosinusitis, asthma and chronic obstructive pulmonary disease, supplemented by programs targeting pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders. The company combines small-molecule and small-nucleic-acid drugs with inhalation delivery technologies—such as liposomal and siRNA platforms—to enhance efficacy-safety profiles through localized administration.</p>\n<p>The board of CF PharmTech states that the partnership is expected to improve patient accessibility and bolster commercialization efficiency amid China’s large, long-term respiratory patient base. The agreement does not constitute a notifiable transaction under Hong Kong listing rules.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in CF PharmTech’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1185911468","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185911468","pubTimestamp":1774225287,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. (CF PharmTech) announced that it entered into a strategic cooperation agreement with JD Health International Inc. on 20 March 2026, appointing JD Health as the exclusive online...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech与京东健康签署三年战略合作伙伴关系，独家上线呼吸产品组合","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. (CF PharmTech) announced that it entered into a strategic cooperation agreement with JD Health International Inc. on 20 March 2026, appointing JD Health as the exclusive online launch platform for a series of new products in respiratory and rhinology therapeutics over the next three years.\nUnder the agreement, JD Health will:  \n1) Deploy its e-commerce and supply-chain infrastructure to support online sales and patient-service operations for CF PharmTech’s upcoming products;  \n2) Leverage its prescription‐management and patient-administration capabilities to accelerate commercialization efficiency;  \n3) Collaborate with CF PharmTech on internet-based chronic-disease management models.\nCF PharmTech’s pipeline spans allergic rhinitis, chronic rhinosinusitis, asthma and chronic obstructive pulmonary disease, supplemented by programs targeting pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders. The company combines small-molecule and small-nucleic-acid drugs with inhalation delivery technologies—such as liposomal and siRNA platforms—to enhance efficacy-safety profiles through localized administration.\nThe board of CF PharmTech states that the partnership is expected to improve patient accessibility and bolster commercialization efficiency amid China’s large, long-term respiratory patient base. The agreement does not constitute a notifiable transaction under Hong Kong listing rules.\nShareholders and potential investors are advised to exercise caution when dealing in CF PharmTech’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185911468","isCrawlerRequest":true}